COMPANION DIAGNOSTICS MARKET TO SURPASS US$ 5.0 BILLION BY 2024 : CMI
Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/109
The U.S. FDA lays emphasis on regulatory clearance of companion diagnostics, in its recent draft guidance in 2016, before approving any oncology product that requires and in-vitro diagnostic (IVD) companion diagnostic device for tis safe and effective use. Therefore, drug developers and diagnostic test manufacturers need to work in close collaborations in order to avoid any regulatory bottlenecks. AstraZeneca plc struck a deal with Abbott Laboratories, Inc. in 2015 to develop a companion diagnostic test for tralokinumab, used for treating severe asthma. If successful, this would be the first companion diagnostic test developed for asthma. Moreover, AstraZeneca expects half of its drug launches to include companion diagnostic by 2020. This is a major factor implying the importance of companion diagnostics in treating chronic diseases.
Simultaneous development of a companion diagnostic test and the drug candidate has its own set of pros and cons that act as a trade-off for pharmaceutical companies. Developing companion diagnostic risks holding up of effective drug therapies, and making major investments on companion diagnostics early is a perceived risk, as many drug candidates fail to make it to the market. However, personalized medicine is the emerging therapeutic approach for cancer and other chronic therapies. Thus, developing a companion diagnostic for faster FDA approval makes it imperative for researchers to invest in the development of CDx tests.
Agilent technologies, Inc. announced the extended use of its CE approved Dako PD-L1 IHC 22C3 pharmDx in January 2017, in determining PD-L1 expression status in patients with metastatic non-small cell lung cancer (NSCLC). This device helps determine the expression level of PD-L1 in both untreated and previously treated metastatic NSCLC patients with KEYTRUDA (pembrolizumab), a first-line treatment drug for metastatic NSCLC. With this approval, patients with metastatic NSCLC and in the second-line or later treatment settings can also be identified for treatment with KEYTRUDA.
Invivoscribe Technologies Inc., has companion diagnostics development deal with Novartis AG and Astellas Pharma Inc. Invivoscribe Technologies Inc. has developed a companion diagnostic test for FLT3, a biomarker for the stratification and prognosis of acute myeloid leukemia (AML). This CDx is under the U.S. FDA review for its use with PKC412 (midostaurin) an investigational drug for adults with newly-diagnosed AML and who are FLT3 mutation-positive. If granted approval the LeukoStrat CDx FLT3 Mutation Assay would be the first CDx for AML.
Approval of the drug and CDx test at the same time is difficult. However, the endeavor to develop effective targeted therapies at low cost and faster time to market would encourage more drug developers to conduct clinical trials with diagnostics as part of the inclusion/exclusion criteria.
Key takeaways of the global companion diagnostics market:
The global companion diagnostics market is expected to expand at a CAGR of 12% during the forecast period (2016–2024). Improved clinical outcomes, reduced total research cost and faster time to market are some of the major factors driving collaborations and CDx development globally
To know the latest trends and insights prevalent in the companion diagnostic market, click the link below: https://www.coherentmarketinsights.com/market-insight/companion-diagnostics-market-109
The breast cancer application in the global companion diagnostics market was estimated to be the largest in 2015 and is expected to dominate the companion diagnostics market throughout the forecast period in terms of value. This is owing to high number of approved brands with CDx tests, driving adoption of these products in treatment of breast cancer.
In terms of technology, the gene sequencing method segment is expected to expand at a CAGR of 12.6% during the forecast period. Growth of the segment is mainly attributed to increasing focus on identification of genetic mutations that can help in precise identification of the treatment approach for cancer therapies.
The global companion diagnostics market is characterized by strategic research and development collaborations among the drug and diagnostic test developers. According to the Wildwood Ventures Ltd., the number of global deal in companion diagnostics market has increased from 13 in 2007 to 66 in 2013.
Some of the major players in the global companion diagnostics market include Abbott Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare, Qiagen N.V., Roche Diagnostics, Biomérieux, Myriad Genetics, Inc., bioMérieux SA, and Siemens Healthcare
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release COMPANION DIAGNOSTICS MARKET TO SURPASS US$ 5.0 BILLION BY 2024 : CMI here
News-ID: 449529 • Views: 176
More Releases from COMPANION DIAGNOSTICS MARKET
Companion Diagnostics Market Size 2020-26, QIAGEN, Agilent, BioMerieux
The latest study on the Global Companion Diagnostics market report represents a deep appraisal of the international industry. The research report on the worldwide Companion Diagnostics market 2020-2026 sheds light on qualitative as well as quantitative insights, historical Companion Diagnostics industry status and authorized projection related to the Companion Diagnostics market size. Each and every segment exhibited in this report are discovered through verifiable research methods and techniques. It also
Companion Diagnostics Market to Witness Steady Growth at 32.3% CAGR During 2016 …
Researchmoz added Most up-to-date research on "Companion Diagnostics: Technologies and Markets" to its huge collection of research reports. Report Highlights The global market for companion diagnostics reached nearly $3.2 billion in 2015. This market is expected to increase from $4.3 billion in 2016 to nearly $17.6 billion in 2021 at a compound annual growth rate (CAGR) of 32.3% for 2016-2021. Report Includes An overview of the market for companion diagnostics, including existing products on
Companion Diagnostics Market - Analysis And Forecast (2016-2024): Market Shares …
Companion diagnostic (CDx) is a diagnostic tool used to determine the suitability of a drug therapy to the patient. It has become a critical part of targeted cancer therapy that allows for development of personalized therapy can be developed and administered to the patient. Whole blood samples, tissues samples, or buccal samples are collected and tested for diagnosis and identification of targeted disease biomarker. CDx is usually utilized in identifying
CMI Releases New Report on the Companion Diagnostics Market,2017-2024.
The Global Companion Diagnostics (CDx) Market was valued at US$ 1,614.5 million in 2015 and is projected to expand at a CAGR of 12.0% during the forecast period (2016–2024), as highlighted in a new report published by Coherent Market Insights. Development of multiple biomarkers and targeted drug therapy is boosting research and development collaboration among the industry players. This is expected to improve the time to market for companion diagnostic
More Releases for CDx
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Mark …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market by companies, region, type and end-use industry. Get Sample Copy of This Report @ https://www.researchtrades.com/request-sample/1644663 In 2017, the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size was million US$ and it is expected to reach million US$ by the end of 2025,
The companion diagnostics (CDx) market is projected to grow with a good CAGR dur …
The recent study on the companion diagnostics market covers an in-depth analysis of the market on the basis of technology, indication, and geography. The report also covers the country level analysis within the regions as well. In addition, the report covers the key trends in the market along with drivers and restraints during the forecast period 2018-2023. According to the report titled “Companion Diagnostics (CDx) Market - Forecasts From 2018
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2018 …
The Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2018 to 2025 renders deep perception of the key regional market status of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. The report on “Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market” is a professional report
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Sale …
This report studies the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, analyzes and researches the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Qiagen NV GE Healthcare Agilent Technologies F Hoffman La Roche Foundation Medicine Thermo Fisher Scientific Inc. Leica Biosystems Nussloch GmBH Pfizer Get the sample copy of report : https://www.marketresearchreports.biz/sample/sample/1486733 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast
Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Mark …
Qyresearchreports include new market research report "Global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size,Status and Forecast 2025" to its huge collection of research reports. The report on the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market covers all major factors such as growth drivers, leading segments, market size estimates, and technological advancements for the 2018-2025 forecast period. These factors hold significance for a qualitative and quantitative analysis of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Size …
This report provides in depth study of “Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of